Chintakuntlawar Ashish V, Okuno Scott H, Price Katharine A
Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA.
Cancers Head Neck. 2016 Sep 1;1:11. doi: 10.1186/s41199-016-0011-z. eCollection 2016.
Salivary gland carcinomas are notoriously resistant to therapy and no standard of care exists. Due to the rarity of these malignancies, various histologies, and wide ranging clinical behavior it has been difficult to standardize systemic therapy. We have reviewed clinical prospective studies in the last 15 years with salivary gland malignancies involving cytotoxic chemotherapy and biologic agents including targeted therapies such as anti-HER-2, anti-EGFR therapies, and therapies directed at c-kit. Although the results of most trials are modest at best, there has been an increase in studies for salivary cancer in recent years and there are several promising treatment approaches in evolution. Every effort should be made to treat salivary gland malignancies under a clinical protocol and/or at a large multidisciplinary practice with clinicians experienced in treating these malignancies.
涎腺癌对治疗具有众所周知的耐药性，且不存在标准治疗方案。由于这些恶性肿瘤罕见、组织学类型多样以及临床行为广泛，因此难以规范全身治疗。我们回顾了过去15年中关于涎腺恶性肿瘤的临床前瞻性研究，这些研究涉及细胞毒性化疗和生物制剂，包括抗HER-2、抗EGFR等靶向治疗以及针对c-kit的治疗。尽管大多数试验结果充其量只是一般，但近年来关于涎腺癌的研究有所增加，并且有几种有前景的治疗方法正在发展中。应尽一切努力在临床方案下和/或在有治疗这些恶性肿瘤经验的临床医生参与的大型多学科实践中治疗涎腺恶性肿瘤。
